Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | PI4KA | P42356 | 10/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21128139 | 0.83 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10442147 | 0.75 | YTHDC1 (0.62) | ADORA2AADORA1ADORA2BAHCYADORA3 | |
| SCHEMBL24377187 | 0.75 | CDK1 (0.40) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL106573 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL580610 | 0.74 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24709952 | 0.74 | ADORA2A (0.68) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL7140260 | 0.73 | ADORA2A (0.96) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL7147821 | 0.73 | ADORA2A (0.96) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.72 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.72 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240060140-A1 | IGH REARRANGEMENTS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| EP-4267767-A1 | IGH REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4223770-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230193282-A1 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| EP-1381694-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS Pharmaceuticals, Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6653067-B1 | Contacting with modified/unmodified test molecule and dissociating; comparing the unseparated complexes; mass spectrometry; use in drug discovery | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002068691-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | ADORA2A 4349/4885ADORA1 4554/4885PI4KA 4481/4885 |
| US-20230193282-A1 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | MTPN, UTRN, CAPNS1 | ADORA2A 2146/4885ADORA1 2988/4885PI4KA 4622/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | ADORA2A 4374/4885ADORA1 4143/4885PI4KA 1930/4885 |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | ADORA2A 4374/4885ADORA1 4143/4885PI4KA 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.